Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer

Andrew J. Dannenberg, Nasser K. Altorki, Jay O. Boyle, Chau Dang, Louise R. Howe, Babette B. Weksler, Kotha Subbaramaiah

Research output: Contribution to journalReview articlepeer-review

495 Scopus citations


Understanding the mechanisms underlying carcinogenesis provides insights that are necessary for the development of therapeutic strategies to prevent cancer. Chemoprevention - the use of drugs or natural substances to inhibit carcinogenesis - is an important and rapidly evolving aspect of cancer research. We discuss evidence that cyclooxygenase 2 (COX 2), an inducible form of the enzyme, is a potential pharmacological target to prevent cancer. Key data implicating a causal relation between increased activity of COX 2 and carcinogenesis and possible mechanisms of action of COX 2 in this context are covered. Importantly, selective COX 2 inhibitors appear to be safe enough in human beings to allow large-scale clinical testing in healthy people. Several chemoprevention trials using selective COX 2 inhibitors are underway.

Original languageEnglish (US)
Pages (from-to)544-551
Number of pages8
JournalLancet Oncology
Issue number9
StatePublished - Sep 1 2001

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer'. Together they form a unique fingerprint.

Cite this